Physician profile
Octavian Sharp
NPI 1184938201
$8,210.62
in general payments reported to CMS, 2019-2025
30 companies · $786 in 2025
The $786 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,462 · 2022: $2,982 · 2023: $1,820 · 2024: $161 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Education: $528 · Travel and Lodging: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.07 |
| Education | $528.46 |
| Travel and Lodging | $440.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,103.30 | 2021-2022 | |
| Nevro Corp. | $1,255.50 | 2021-2023 | Senza |
| Boston Scientific Corporation | $702.34 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $584.26 | 2022-2023 | Nalu Neurostimulation System |
| Abbvie INC. | $502.95 | 2021-2025 | |
| Novo Nordisk INC | $475.38 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Grt US Holding, INC. | $362.09 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $271.48 | 2021-2023 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $226.29 | 2022 | |
| Abbott Laboratories | $195.70 | 2021-2025 | Freestyle Libre 3, Confirm Rx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.66 | 2021-2023 | Relistor |
| Biohaven Pharmaceuticals, INC. | $167.15 | 2021 | |
| Insulet Corporation | $148.52 | 2025 | Omnipod, Omnipod |
| Almatica Pharma LLC | $148.21 | 2021 | |
| Collegium Pharmaceutical, INC. | $127.00 | 2021-2023 | Belbuca |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $118.23 | 2025 | |
| Lilly USA, LLC | $115.41 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $88.38 | 2023 | |
| Stimwave Technologies Incorporated | $65.20 | 2021-2022 | |
| Bioventus LLC | $56.47 | 2022 | |
| Glaxosmithkline, LLC. | $49.30 | 2025 | Trelegy Ellipta |
| Protega Pharmaceutials INC | $44.81 | 2023 | Roxybond |
| Tersera Therapeutics LLC | $36.81 | 2022 | |
| Exact Sciences Corporation | $34.76 | 2025 | The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $33.27 | 2021 | |
| Vertos Medical, INC. | $25.72 | 2023 | Mild Device Kit |
| Corcept Therapeutics | $24.40 | 2025 | Korlym |
| Averitas Pharma INC. | $22.67 | 2023 | Qutenza |
| Merck Sharp & Dohme LLC | $18.46 | 2024 | Capvaxive |
| Curonix LLC | $16.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Octavian Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.